The global axitinib market is anticipated to grow at a CAGR of nearly 3.5% during the forecast period (2022-2028). Axitinib is an oral VEGFR and kinase inhibitor used for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy. The major factor expected to drive the market growth is the increasing […]
